Intech Biopharm Corporation

Taipei Exchange 6461.TWO

Intech Biopharm Corporation Price to Sales Ratio (P/S) on January 14, 2025: 122.83

Intech Biopharm Corporation Price to Sales Ratio (P/S) is 122.83 on January 14, 2025, a -11.79% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Intech Biopharm Corporation 52-week high Price to Sales Ratio (P/S) is 162.35 on August 14, 2024, which is 32.18% above the current Price to Sales Ratio (P/S).
  • Intech Biopharm Corporation 52-week low Price to Sales Ratio (P/S) is 118.83 on August 06, 2024, which is -3.25% below the current Price to Sales Ratio (P/S).
  • Intech Biopharm Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 141.81.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Taipei Exchange: 6461.TWO

Intech Biopharm Corporation

CEO Mr. Wei-Shiu Wu
IPO Date July 15, 2014
Location
Headquarters No. 36, Ruiguang Road
Employees 82
Sector Health Care
Industries
Pharmaceuticals
Description

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email